Form 8-K - Current report:
SEC Accession No. 0001193805-24-001079
Filing Date
2024-09-03
Accepted
2024-09-03 08:30:38
Documents
14
Period of Report
2024-08-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 e663859_8k-immunic.htm   iXBRL 8-K 20450
2 e663859_ex10-1.htm EX-10.1 6044
  Complete submission text file 0001193805-24-001079.txt   202243

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE imux-20240829.xsd EX-101.SCH 3003
4 XBRL LABEL FILE imux-20240829_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE imux-20240829_pre.xml EX-101.PRE 22351
16 EXTRACTED XBRL INSTANCE DOCUMENT e663859_8k-immunic_htm.xml XML 3779
Mailing Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036
Business Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036 (332) 255-9818
IMMUNIC, INC. (Filer) CIK: 0001280776 (see all company filings)

EIN.: 562358443 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36201 | Film No.: 241272120
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)